Andrew J. Fromkin sold $517k of IMVT
director at Immunovant, Inc.. 22,249 shares at an average of $23.25, traded Dec 1, 2025, filed Dec 3, 2025.
Score components
- +15RoleDirector
- +18Trade size$517k at market
- +5Share of holdings soldSold 21% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +14.1%, 3m +19.2%, 6m +37.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001764013-25-000160, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 1, 2025 | SOpen-market sale Common Stock10b5-1 | -19,351 | $23.14 | $448k | 88,750 | Dec 3, 2025 |
| Dec 1, 2025 | SOpen-market sale Common Stock10b5-1 | -2,898 | $23.95 | $69k | 85,852 | Dec 3, 2025 |
Related signals
Other insiders at Immunovant, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 16, 2026 | Immunovant, Inc. | Melanie Gloria Chief Operating Officer | $72k 2,241 shares | -1% | |
| Pro nowfree Oct 16, 2026 | Immunovant, Inc. | Jay S Stout Chief Technology Officer | $122k 3,809 shares | -2% | |
| Pro nowfree Oct 16, 2026 | Immunovant, Inc. | Christopher Van Tuyl Chief Legal Officer | $43k 1,327 shares | -1% | |
| 35Weak | Immunovant, Inc. | Eric Venker Chief Executive Officer | $120k 3,506 shares | -1% | |
| 40Moderate | Immunovant, Inc. | Christopher Van Tuyl Chief Legal Officer | $103k 2,846 shares | -2% | |
| 0Weak | Immunovant, Inc. | Atul Pande director | $65k 1,500 shares | -1% | |
| 39Weak | Immunovant, Inc. | Melanie Gloria Chief Operating Officer | $135k 3,056 shares | -1% | |
| 50Moderate | Immunovant, Inc. | Tiago Girao Chief Financial Officer | $263k 6,798 shares | -3% | |
| 2Weak | Immunovant, Inc. | Atul Pande director | $60k 1,500 shares | -1% | |
| 40Moderate | Immunovant, Inc. | Jay S Stout Chief Technology Officer | $111k 2,857 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.